SAN DIEGO--(BUSINESS WIRE)--Nov. 30, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced the appointment of Srdjan (Serge) Stankovic,
M.D., M.S.P.H., as Executive Vice President, Head of Research and
Development. With a background in clinical and academic psychiatry, Dr.
Stankovic brings over 20 years of executive level experience in drug
development and clinical and medical affairs.
“I am delighted to welcome Serge to our team,” said Steve Davis,
ACADIA’s President and Chief Executive Officer. “Serge has a track
record of transforming promising research into important medicines that
address unmet needs of patients. We look forward to his contributions as
we advance NUPLAZID™ through NDA review for Parkinson’s disease
psychosis, prepare for the planned commercialization of NUPLAZID in the
United States and continue our efforts to explore the full potential of
NUPLAZID to treat patients suffering from additional CNS disorders.”
“There is a strong need for continued innovation in the treatment of CNS
disorders such as Parkinson’s disease, Alzheimer’s disease, and
schizophrenia,” said Dr. Stankovic. “ACADIA is at the forefront in
developing groundbreaking medicines to treat debilitating symptoms
associated with these diseases. I look forward to leading the team in
advancing the promising development programs with NUPLAZID.”
Dr. Stankovic has built and led multidisciplinary teams for small
molecules and biologics in therapeutic areas including neurology,
psychiatry, oncology, cardiology and pain. He has led teams to
achieve approvals of KEPPRA®, FENTORA®, TREANDA®,
NUVIGIL® and ARISTADA™.
Dr. Stankovic most recently served as Senior Vice President of Clinical
Development and Medical Affairs at Alkermes plc. from 2013 to 2015.
Prior to Alkermes, he held the position of Senior Vice President and
Head of Global Clinical Development for Teva Pharmaceuticals Ltd. He was
appointed to this role following Teva’s acquisition of Cephalon, Inc.
where he served as Senior Vice President, Worldwide Clinical Research.
Dr. Stankovic also held executive positions in research and development
at Forest Laboratories, Inc., Neurogen Corporation, Johnson and Johnson,
and UCB. Dr. Stankovic received his M.D. from the University of Belgrade
and holds a Master of Science in Public Health from the University of
Alabama at Birmingham.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA has a pipeline of product
candidates led by NUPLAZID™ (pimavanserin), for which we have submitted
a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA
and which has the potential to be the first drug approved in the United
States for this condition. The FDA has classified the NUPLAZID NDA as
having Priority Review status. Pimavanserin is also in Phase II
development for Alzheimer’s disease psychosis and has successfully
completed a Phase II trial in schizophrenia. ACADIA also has
clinical-stage programs for glaucoma and, in collaboration with
Allergan, Inc., for chronic pain. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the potential for NUPLAZID
(pimavanserin) to be the first drug approved in the United States for
Parkinson’s disease psychosis (PDP) and the potential timing of such
approval, if approved at all, by the FDA; the potential contributions of
Dr. Stankovic to ACADIA; the progress, timing and results of ACADIA’s
drug discovery and development programs, either alone or with a partner,
including the progress and expected timing of clinical trials; the
ability of NUPLAZID to treat debilitating symptoms associated with
multiple CNS disorders; the potential of the NUPLAZID development
programs; and the benefits to be derived from ACADIA’s product
candidates, including pimavanserin. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to various
factors, including the risks and uncertainties inherent in drug
discovery, development, approval and commercialization, and
collaborations with others, and the fact that past results of clinical
trials and past regulatory decisions may not be indicative of future
trial results or future regulatory decisions, respectively. For a
discussion of these and other factors, please refer to ACADIA’s annual
report on Form 10-K for the year ended December 31, 2014 as well as
ACADIA’s subsequent filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is made
under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151130005324/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director of